Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy

Autor: Bunupuradah, T, Chetchotisakd, P, Jirajariyavej, S, Valcour, V, Bowonwattanuwong, C, Munsakul, W, Klinbuayaem, V, Prasithsirikul, W, Sophonphan, J, Mahanontharit, A, Hirschel, B, Bhakeecheep, S, Ruxrungtham, K, Ananworanich, J, HIV STAR Study Group
Rok vydání: 2012
Předmět:
Zdroj: Journal of neurovirology, vol 18, iss 6
Bunupuradah, T; Chetchotisakd, P; Jirajariyavej, S; Valcour, V; Bowonwattanuwong, C; Munsakul, W; et al.(2012). Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.. Journal of neurovirology, 18(6), 479-487. doi: 10.1007/s13365-012-0127-9. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/1pf2h4ht
DOI: 10.1007/s13365-012-0127-9.
Popis: We compared rates of neurocognitive impairment (NCI) among 93 Thai adults failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) before and after switching to lopinavir/ritonavir monotherapy (mLPV/r) vs. tenofovir/lamivudine/LPV/r (TDF/3TC/LPV/r). Participants completed the Color Trails 1 and 2, Digit Symbol, and Grooved Pegboard at weeks 0, 24, and 48. We calculated z-scores using normative data from 451 healthy HIV-negative Thais. We defined NCI as performance of
Databáze: OpenAIRE